Cayuga Therapeutics

Cayuga Therapeutics is a preclinical-stage biotechnology company dedicated to developing innovative therapies for bleeding and thrombotic disorders. The company's research focuses on the role of polyphosphate, a molecule released by platelets that accelerates blood clotting and promotes inflammation. By developing specific inhibitors of polyphosphate, Cayuga aims to create a new class of antithrombotic agents that prevent unwanted blood clots without the significant bleeding risks associated with current anticoagulants. The company's technology is based on foundational research from the University of Michigan and the University of Illinois at Urbana-Champaign.